HPV Vaccine
Cervical cancer · Oropharyngeal cancer · Anal cancer · Penile cancer · Vulvar/vaginal cancer · Genital warts
Human papillomavirus is the most common sexually transmitted infection — nearly all sexually active adults will be infected at some point. Most infections clear spontaneously, but persistent infection with high-risk strains (16, 18) causes nearly all cervical cancers and a growing proportion of head and neck cancers. Gardasil 9 covers 9 HPV strains responsible for ~90% of cervical cancers and 90% of genital warts.
Overall Benefit Score
Default scenario · 12-month-old · US community (92% vax rate)
Score for your child →The evidence moderately supports this vaccine for your child's situation. Benefits outweigh risks but some factors in your scenario lower the urgency.
📊 Evidence Scores
Scores computed from peer-reviewed data using VaxFact's evidence model. Based on default scenario (12-month-old, standard US community).
🦠 Disease Burden
Human papillomavirus is the most common sexually transmitted infection — nearly all sexually active adults will be infected at some point. Most infections clear spontaneously, but persistent infection with high-risk strains (16, 18) causes nearly all cervical cancers and a growing proportion of head and neck cancers. Gardasil 9 covers 9 HPV strains responsible for ~90% of cervical cancers and 90% of genital warts.
Cervical cancer treatment involves surgery, radiation, and chemotherapy with significant impacts on fertility, sexual function, and long-term health. Oropharyngeal cancer (HPV-related) has a better prognosis than tobacco-related oral cancers but involves disfiguring surgery and radiation. Genital warts cause significant psychological distress and social stigma.
🛡️ Vaccine Effectiveness
Antibody levels remain elevated for 12+ years of follow-up with no evidence of waning protection. Modeling projects durable protection for at least 20–30 years. No booster currently recommended for immunocompetent individuals.
Vaccine does not protect against strains not covered. Pre-existing infections at vaccination time are not cleared by vaccine. Greatest efficacy when administered before sexual debut.
⚠️ Adverse Events & Side Effects
All probabilities are per 100,000 doses administered, sourced from VAERS, Vaccine Safety Datalink, and post-licensure surveillance studies.
Common Side Effects
Rare Serious Events
📅 Vaccine Schedule
Catch-up vaccination recommended through age 26. Ages 27–45: shared clinical decision-making based on risk. Immunocompromised individuals of any age: 3-dose series.
⚖️ Benefits vs. Considerations
✓ Benefits
- Near-complete prevention of cervical cancer (89% reduction in Scotland birth cohort)
- Prevents cancers in males: penile, anal, oropharyngeal
- Eliminates genital warts (HPV 6 and 11) in >90% of cases
- Greatest efficacy when given before first sexual exposure — ages 9–12 offer highest protection
- Australia approaching near-elimination of cervical cancer as a public health problem
- 18 years of post-licensure safety data across 500+ million doses
↕ Considerations
- Does not protect against strains not covered (~10% of cervical cancers caused by other HPV strains)
- Does not clear existing infections — benefit reduced if given after sexual debut
- Syncope risk in adolescents requires 15-minute post-vaccination observation
- Japan suspended active recommendation for 8 years due to adverse event concerns — regulatory controversy remains
- 3-dose schedule required for older adolescents and adults
🔬 What Some Researchers Question
These are legitimate scientific debates — not fringe claims. They represent areas of ongoing research or policy disagreement among credentialed experts.
- Japan's Ministry of Health received thousands of reports of 'complex regional pain syndrome,' POTS, and cognitive symptoms following HPV vaccination, prompting suspension of the proactive recommendation from 2013–2021. The WHO's GACVS investigated and concluded the reported rates were not higher than background — but critics argue the investigation was insufficiently independent and the case definitions were inconsistent (Martínez-Lavín et al., 2017).
- Nordic surveillance studies (Denmark, Sweden) found elevated rates of POTS and chronic fatigue in HPV-vaccinated females compared with HPV-unvaccinated controls, though these findings have been contested due to confounding (Donegan et al., 2019 vs. Grimaldi-Bensouda et al., 2017).
- Health economists have questioned whether vaccinating males against HPV is cost-effective in countries with high female vaccination coverage, where herd protection to males may be sufficient — arguing resources would achieve more health per dollar if redirected (Chesson et al., 2018).
🌫️ Scientific Uncertainties
Honest acknowledgment of what we don't yet know with confidence.
- POTS/chronic fatigue syndrome signal: Japan, Denmark, and Ireland received many reports; pharmacovigilance studies have not confirmed causation but the signal has not been definitively ruled out in all analyses (Brinth et al., 2015; WHO GACVS 2017)
- Long-term duration of protection beyond 15 years — extrapolated from antibody modeling; real-world cancer endpoints require longer follow-up
- Whether vaccinating boys provides sufficient herd protection to justify cost vs. vaccinating boys directly (different countries have reached different conclusions)
💉 Related Vaccines
Vaccines often given together or covering related diseases.
🌍 International Policy Comparison
How different countries approach this vaccine — revealing where global consensus is strong vs. where policy diverges.